Dr. Kowalski has more than 20 years of experience in the pharmaceutical and biotech industry. He is a clinical leader, developing regulatory strategy and global clinical development plans for a variety of product types including small molecules, biologics (monoclonals, immunoconjugates, siRNAs) and vaccines, while working in a range of indications, including oncology, infectious diseases, urology, analgesia, allergy, rheumatology and metabolic disorders.

He brings to Eupraxia experience with clinical study design, database design and authoring protocols for Phase 1 through 3 clinical trials, as well as medical monitoring and pharmacovigilance services for Phase 1 through 4 clinical trials, plus data analysis and writing of clinical study reports. Dr. Kowalski held multiple senior roles, including Chief Medical Officer, at Sierra Oncology, a public company acquired by GSK plc in 2022 for US$1.9 billion.